✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Shanghai RAAS Blood Products Co Ltd

Common Name
Shanghai RAAS Blood Products
Country
China (Mainland)
Sector
Healthcare
Industry
Biotechnology
Employees
3,350
Ticker
002252
Exchange
SHENZHEN STOCK EXCHANGE
Description
Shanghai RAAS Blood Products Co., Ltd. is a leading biotechnology company specializing in the production and distribution of blood plasma-derived products. Operating within the pharmaceutical sector, ...

Disclosures of Shanghai RAAS Blood Products

Explore Shanghai RAAS Blood Products's complete collection of publicly available corporate disclosures, including annual reports, sustainability reports, financial statements, ESG data spreadsheets, and related web publications. Each document is sourced directly from Shanghai RAAS Blood Products's official channels and fully traceable to its official company sources.

The table below lists all of Shanghai RAAS Blood Products's' corporate disclosure by name and reporting period, ensuring full transparency and easy access.

If you want to search across Shanghai RAAS Blood Products's' disclosures for specific data or insights, use our Disclosure Search.

NameReporting Period
Annual Report
2024
Sustainability Report
2024
Responsibility Report
2023
Annual Report
2023
Responsibility Report
2022
Annual Report
2022
Annual Report
2021
Responsibility Report
2021
Annual Report
2020
Responsibility Report
2020
Annual Report
2019
Responsibility Report
2019
Annual Report
2018
Responsibility Report
2018
Responsibility Report
2017
Annual Report
2017
Annual Report
2016
Responsibility Report
2016
Webpage captured from company’s website
2015
Annual Report
2015
Webpage captured from company’s website
2014
Real-Time Disclosures Datafeed

Get Notified Within Seconds of New Corporate Disclosures

Tracenable is building a high-speed disclosure monitoring system that delivers instant alerts when companies publish new reports or data. Could a real-time datafeed (via SFTP, RSS or API) enhance your investment or analytical workflows?